GH1 and cancer: In the last visit, for overall patients with cancers, GH (median: 1.50 vs. 0.90 ng/ml, p = 0.017) and IGF-1 (IGF-1, median: 252 vs. 214 ng/ml, p = 0.050; ULN, 1.01 vs. 0.91, p = 0.070) tended to elevate, but the acromegaly-controlled rate was similar (46.4% vs. 52.8%).